Oxford launches first human aerosol TB challenge trial
The University of Oxford in partnership with the Coler Lab at Seattle Children’s Research Institute (SCRI) has begun a new clinical trial called TB045, which aims to test tuberculosis (TB) vaccine safety and the host immune response in a first-in-man aerosol mycobacterial challenge infection model with healthy adult volunteers. TB is a disease caused by the bacterium Mycobacterium tuberculosis and in 2023 was the leading cause of death from an…

